These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 32458247

  • 1. Relationship between post-IVIG IgG levels and clinical outcomes in Kawasaki disease patients: new insight into the mechanism of action of IVIG.
    Goto R, Inuzuka R, Shindo T, Namai Y, Oda Y, Harita Y, Oka A.
    Clin Rheumatol; 2020 Dec; 39(12):3747-3755. PubMed ID: 32458247
    [Abstract] [Full Text] [Related]

  • 2. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan.
    Takekoshi N, Kitano N, Takeuchi T, Suenaga T, Kakimoto N, Suzuki T, Kada TT, Shibuta S, Tachibana S, Murayama Y, Yamaga H, Suzuki H.
    JAMA Netw Open; 2022 Jun 01; 5(6):e2216642. PubMed ID: 35696166
    [Abstract] [Full Text] [Related]

  • 3. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W, Hu P.
    Pediatr Rheumatol Online J; 2019 Jul 31; 17(1):53. PubMed ID: 31366406
    [Abstract] [Full Text] [Related]

  • 4. Sodium-containing versus sodium-trace preparations of IVIG for children with Kawasaki disease in the acute phase.
    Suzuki T, Michihata N, Aso S, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2021 Nov 31; 180(11):3279-3286. PubMed ID: 33973071
    [Abstract] [Full Text] [Related]

  • 5. IgG levels in Kawasaki disease and its association with clinical outcomes.
    Yamazaki-Nakashimada MA, Gámez-González LB, Murata C, Honda T, Yasukawa K, Hamada H.
    Clin Rheumatol; 2019 Mar 31; 38(3):749-754. PubMed ID: 30343342
    [Abstract] [Full Text] [Related]

  • 6. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
    Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R.
    Paediatr Int Child Health; 2018 Aug 31; 38(3):209-212. PubMed ID: 29768976
    [Abstract] [Full Text] [Related]

  • 7. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
    Iio K, Morikawa Y, Miyata K, Kaneko T, Misawa M, Yamagishi H, Miura M.
    J Pediatr; 2022 Jan 31; 240():158-163.e4. PubMed ID: 34461064
    [Abstract] [Full Text] [Related]

  • 8. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin.
    Matsuoka R, Furuno K, Nanishi E, Onoyama S, Nagata H, Yamamura K, Sugitani Y, Kuraoka A, Mizuno Y, Sagawa K, Honjo S, Hara T, Ohga S.
    J Pediatr; 2020 Dec 31; 227():224-230.e3. PubMed ID: 32810506
    [Abstract] [Full Text] [Related]

  • 9. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, Mossberg M, Kucera F, Tulloh R, Standing JF, Swallow V, McCormack R, Herberg J, Levin M, Wan M, Klein N, Connon R, Walker AS, Brogan P.
    Trials; 2023 Jan 26; 24(1):60. PubMed ID: 36703139
    [Abstract] [Full Text] [Related]

  • 10. Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease.
    Yanagimoto K, Nomura Y, Masuda K, Hirabayashi M, Morita Y, Yoshishige M, Ueno K, Eguchi T, Kawano Y.
    Int Arch Allergy Immunol; 2014 Jan 26; 164(2):83-8. PubMed ID: 24903098
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.
    Liu J, Ye B, Su D, Qin S, Zhao W, Pang Y.
    Clin Rheumatol; 2023 Jan 26; 42(1):167-177. PubMed ID: 36129563
    [Abstract] [Full Text] [Related]

  • 12. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
    Friedman KG, Gauvreau K, Hamaoka-Okamoto A, Tang A, Berry E, Tremoulet AH, Mahavadi VS, Baker A, deFerranti SD, Fulton DR, Burns JC, Newburger JW.
    J Am Heart Assoc; 2016 Sep 15; 5(9):. PubMed ID: 27633390
    [Abstract] [Full Text] [Related]

  • 13. Association between intravenous immunoglobulin dose and outcomes in patients with acute Kawasaki disease.
    Michihata N, Suzuki T, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2022 Oct 15; 181(10):3607-3615. PubMed ID: 35925450
    [Abstract] [Full Text] [Related]

  • 14. Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease.
    Burns JC, Touma R, Song Y, Padilla RL, Tremoulet AH, Sidney J, Sette A, Franco A.
    Autoimmunity; 2015 May 15; 48(3):181-8. PubMed ID: 25822882
    [Abstract] [Full Text] [Related]

  • 15. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V.
    Turk J Pediatr; 2019 May 15; 61(5):648-656. PubMed ID: 32104995
    [Abstract] [Full Text] [Related]

  • 16. Correlation of Coronary Artery Abnormalities with Fever Pattern in Patients with Kawasaki Disease.
    Tanaka A, Inoue M, Hoshina T, Koga H.
    J Pediatr; 2021 Sep 15; 236():95-100. PubMed ID: 34019881
    [Abstract] [Full Text] [Related]

  • 17. Risk Factors for Coronary Artery Aneurysm in a Chinese Pediatric Population with Kawasaki Disease at Low Risk of Intravenous Immunoglobulin Resistance: A Retrospective Cohort Study.
    Liu J, Su D, Yuan P, Ye B, Qin S, Pang Y.
    Cardiology; 2023 Sep 15; 148(5):457-468. PubMed ID: 37231847
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 15; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 19. Japanese Kawasaki Disease Scoring Systems: Are they Applicable to the Iranian Population?
    Edraki MR, Mohammadi H, Mehdizadegan N, Ghorashi M, Amoozgar H, Borzouee M, Ajami G, Keshavarz K, Dehghani E, Bahrami R.
    Arch Iran Med; 2020 Jan 01; 23(1):31-36. PubMed ID: 31910632
    [Abstract] [Full Text] [Related]

  • 20. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more.
    Suzuki T, Michihata N, Yoshikawa T, Hata T, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2020 Dec 01; 179(12):1901-1907. PubMed ID: 32862279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.